U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H30O
Molecular Weight 274.4409
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANDROSTENOL

SMILES

[H][C@@]12CC=C[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])C[C@H](O)CC[C@]34C

InChI

InChIKey=KRVXMNNRSSQZJP-PHFHYRSDSA-N
InChI=1S/C19H30O/c1-18-9-3-4-16(18)15-6-5-13-12-14(20)7-11-19(13,2)17(15)8-10-18/h3,9,13-17,20H,4-8,10-12H2,1-2H3/t13-,14+,15-,16-,17-,18-,19-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H30O
Molecular Weight 274.4409
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Androstenol (5α-androst-16-en-3α-ol), a pheromone that acts as a potent positive allosteric modulator of the GABA-A receptor. Androstenol was first isolated from boar testes, and several animal experiments suggest that androstenol is capable of reducing anxiety, as well as hippocampal epileptogenic activity. It was subsequently detected in humans, (primarily in males), in sweat, urine, plasma, and saliva. Androstenol is also shown to affect hormonal, behavioral and social responses in humans. In animals, androstenol has been found to produce anxiolytic-like, antidepressant-like and anticonvulsant effects.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Sample Use Guides

In Vivo Use Guide
in mice: systemic administration of androstenol (30-50 mg/kg) caused anxiolytic-like effects in mice in the open-field test and elevated zero-maze and antidepressant-like effects in the forced swim test (5-10 mg/kg).
Route of Administration: Intraperitoneal
In Vitro Use Guide
In whole-cell recordings from cerebellar granule cells, androstenol caused a concentration-dependent enhancement of GABA-activated currents (EC(50), 0.4 microM in cultures; 1.4 microM in slices) and prolonged the duration of spontaneous and miniature inhibitory postsynaptic currents. Androstenol (0.1-1 microM) also potentiated the amplitude of GABA-activated currents in human embryonic kidney 293 cells transfected with recombinant alpha1beta2gamma2 and alpha2beta2gamma2 GABA(A) receptors and, at high concentrations (10-300 microM), directly activated currents in these cells.
Substance Class Chemical
Record UNII
48K9VAM062
Record Status Validated (UNII)
Record Version